Skip to main content
Top
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

Effect of DNA methylation inhibitor on RASSF1A genes expression in non-small cell lung cancer cell line A549 and A549DDP

Authors: Duan Mengxi, Wang Qian, Wang Nan, Xiao Xiaoguang, Li Shijun

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Ras association domain family 1A gene (RASSFlA) is a candidate suppressor gene, Lack of RASSF1A expression was found in lung cancer. High DNA methylation at the promoter region is the main reason for inactivating RASSF1A transcription.

Methods

In this study, we examined RASSF1A’s methylation status and its mRNA expression level between non-small cell lung cancer cell line A549 and anti-Cisplatin cell strain A549DDP, Furthermore, methylation of A549DDP was reversed by treatment of 5-Aza-2′ - deoxycytidine (5-Aza-cdR),a DNA methyltransferase inhibitor.

Results

We found that RASSF1A’s methylation status and its mRNA expression were obvious differences between A549 and A549DDP. 5-Aza-CdR treatment remarkablly reduced cell vability of A549DDP. Moreover, 5-Aza-CdR treatment induced A549DDP cell apoptosis in a dose dependent manner with declining cell percentage in S and G2/M stage, and increasing proportion in G0/G1 stage. Cell motility was blocked in G0/G1 stage. All of A549DDP cells showed unmethylated expression, its high methylation status was reversed in a dose-dependent manner within a certain range.

Conclusions

The abnormal gene methylation status of RASSF1A is a molecular biomarker in lung cancer diagnosis, treatment and prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed
2.
go back to reference Jack RH, Davies EA, Møller H: Lung cancer incidence and survival in different ethnic groups in South East England. Br J Cancer. 2011, 105 (7): 1049-1053. 10.1038/bjc.2011.282.PubMedCentralCrossRefPubMed Jack RH, Davies EA, Møller H: Lung cancer incidence and survival in different ethnic groups in South East England. Br J Cancer. 2011, 105 (7): 1049-1053. 10.1038/bjc.2011.282.PubMedCentralCrossRefPubMed
3.
go back to reference Van′t Westeinde SC, van Klaveren RJ: Review screening and early detection of lung cancer. Cancer J. 2011, 17 (1): 3-10. 10.1097/PPO.0b013e3182099319.CrossRefPubMed Van′t Westeinde SC, van Klaveren RJ: Review screening and early detection of lung cancer. Cancer J. 2011, 17 (1): 3-10. 10.1097/PPO.0b013e3182099319.CrossRefPubMed
4.
go back to reference Belani CP, Langer C: Review first-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer. 2002, 38 (Suppl 4): 13-19.CrossRefPubMed Belani CP, Langer C: Review first-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer. 2002, 38 (Suppl 4): 13-19.CrossRefPubMed
5.
go back to reference Jones PA, Baylin SB: Review The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3 (6): 415-428.PubMed Jones PA, Baylin SB: Review The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3 (6): 415-428.PubMed
6.
go back to reference Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000, 25 (3): 315-319. 10.1038/77083.CrossRefPubMed Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000, 25 (3): 315-319. 10.1038/77083.CrossRefPubMed
7.
go back to reference Amaar YG, Minera MG: Ras association domain family 1C protein stimμlates human lung cancer cell proliferation. Am J Physiol Lung Cell Mol Physiol. 2006, 291 (6): 1185-1190. 10.1152/ajplung.00072.2006.CrossRef Amaar YG, Minera MG: Ras association domain family 1C protein stimμlates human lung cancer cell proliferation. Am J Physiol Lung Cell Mol Physiol. 2006, 291 (6): 1185-1190. 10.1152/ajplung.00072.2006.CrossRef
8.
go back to reference Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, Park J: Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 2003, 63 (13): 3743-3746.PubMed Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, Park J: Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 2003, 63 (13): 3743-3746.PubMed
9.
go back to reference Grote HJ: Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer. Verh Dtsch Ges Pathol. 2006, 90: 216-226.PubMed Grote HJ: Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer. Verh Dtsch Ges Pathol. 2006, 90: 216-226.PubMed
10.
go back to reference Liloglou T, Maloney P, Xinarianos G, Hulbert M, Walshaw MJ, Gosney JR, Turnbull L, Field JK: Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Res. 2001, 61 (4): 1624-1628.PubMed Liloglou T, Maloney P, Xinarianos G, Hulbert M, Walshaw MJ, Gosney JR, Turnbull L, Field JK: Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Res. 2001, 61 (4): 1624-1628.PubMed
11.
go back to reference de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC: Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relaps ing non-small cell lung cancer?. Lung Cancer. 2005, 50 (2): 199-209. 10.1016/j.lungcan.2005.05.019.CrossRefPubMed de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC: Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relaps ing non-small cell lung cancer?. Lung Cancer. 2005, 50 (2): 199-209. 10.1016/j.lungcan.2005.05.019.CrossRefPubMed
12.
go back to reference Schneider KU, Dietrich D, Fleischhacker M, Leschber G, Merk J, Schäper F, Stapert HR, Vossenaar ER, Weickmann S, Liebenberg V, Kneip C, Seegebarth A, Erdogan F, Rappold G, Schmidt B: Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer. 2011, 11: 102-10.1186/1471-2407-11-102.PubMedCentralCrossRefPubMed Schneider KU, Dietrich D, Fleischhacker M, Leschber G, Merk J, Schäper F, Stapert HR, Vossenaar ER, Weickmann S, Liebenberg V, Kneip C, Seegebarth A, Erdogan F, Rappold G, Schmidt B: Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer. 2011, 11: 102-10.1186/1471-2407-11-102.PubMedCentralCrossRefPubMed
13.
go back to reference Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006, 66 (10): 5495-5503. 10.1158/0008-5472.CAN-05-2385.CrossRefPubMed Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006, 66 (10): 5495-5503. 10.1158/0008-5472.CAN-05-2385.CrossRefPubMed
14.
go back to reference Aoyama Y, Avruch J, Zhang XF: Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene. 2004, 23 (19): 3426-3433. 10.1038/sj.onc.1207486.CrossRefPubMed Aoyama Y, Avruch J, Zhang XF: Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene. 2004, 23 (19): 3426-3433. 10.1038/sj.onc.1207486.CrossRefPubMed
15.
go back to reference Avruch J, Praskova M, Ortiz-Vega S, Liu M, Zhang XF: Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol. 2006, 407: 290-310.CrossRefPubMed Avruch J, Praskova M, Ortiz-Vega S, Liu M, Zhang XF: Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol. 2006, 407: 290-310.CrossRefPubMed
16.
go back to reference Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F, Clark GJ: A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 2004, 64 (12): 4244-4250. 10.1158/0008-5472.CAN-04-0339.CrossRefPubMed Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F, Clark GJ: A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 2004, 64 (12): 4244-4250. 10.1158/0008-5472.CAN-04-0339.CrossRefPubMed
17.
go back to reference Pfeifer GP, Dammann R: Review methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005, 70 (5): 576-583. 10.1007/s10541-005-0151-y.CrossRef Pfeifer GP, Dammann R: Review methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005, 70 (5): 576-583. 10.1007/s10541-005-0151-y.CrossRef
18.
go back to reference Dammaim R, Sehaqdarsurenqin U, Liu L: Frequent RASSF1A promoter hypermethylation and K- ras mutations in panereatic carcinoma. Oneogene. 2003, 22 (24): 3806-CrossRef Dammaim R, Sehaqdarsurenqin U, Liu L: Frequent RASSF1A promoter hypermethylation and K- ras mutations in panereatic carcinoma. Oneogene. 2003, 22 (24): 3806-CrossRef
19.
go back to reference Dawson MA, Kouzarides T: Review cancer epigenetics: from mechanism to therapy. Cell. 2012, 150 (1): 12-27. 10.1016/j.cell.2012.06.013.CrossRefPubMed Dawson MA, Kouzarides T: Review cancer epigenetics: from mechanism to therapy. Cell. 2012, 150 (1): 12-27. 10.1016/j.cell.2012.06.013.CrossRefPubMed
20.
go back to reference List AF, Vardiman J, Issa JP, DeWitte TM: Review myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program. 2004, 297-317. List AF, Vardiman J, Issa JP, DeWitte TM: Review myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program. 2004, 297-317.
22.
go back to reference Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012, 21 (3): 430-446. 10.1016/j.ccr.2011.12.029.PubMedCentralCrossRefPubMed Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012, 21 (3): 430-446. 10.1016/j.ccr.2011.12.029.PubMedCentralCrossRefPubMed
Metadata
Title
Effect of DNA methylation inhibitor on RASSF1A genes expression in non-small cell lung cancer cell line A549 and A549DDP
Authors
Duan Mengxi
Wang Qian
Wang Nan
Xiao Xiaoguang
Li Shijun
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-91

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine